The study focuses on people with type 2 diabetes and compares two medicines: a tablet that contains dapagliflozin, which belongs to a group called SGLT2i and is taken by mouth, and an injection pen that delivers semaglutide, a drug that works as a GLP-1RA. The purpose of the study is to find out whether these medicines can improve the way the heart works in patients who have insulin resistance in the heart muscle, a condition where the heart cells do not respond well to insulin.
Participants will take the assigned medication for a set period and will undergo special heart scans. One scan uses PET/CT, a technique that shows how the heart uses sugar, and it involves a tiny amount of a substance called 18F-FDG. Another scan, called SPECT, uses a different tiny amount of a substance named 99mTc-Tetrofosmin to look at blood flow in the heart. These images will be used to measure myocardial insulin resistance, coronary flow and overall heart function. After the scans, participants will have regular check‑ins to monitor how they feel and to ensure safety until the final follow‑up visit.
Spain 
